Medifast, Inc. MED
Set alert
At close
Pre-market · Nov 2, 8:24 AM ET
- YTD
- +13.76%
- 1 year
- +0.08%
- Open
- 12.24
- Prev close
- 12.26
- Mkt cap
- 135.87M
- Vol
- 231.89K
- Avg vol
- 143.63K
- EPS
- -3.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.00
- High
- 12.48
- Forward P/E
- 56.17
- Beta
- 1.16
- Short ratio
- 7.68
- Inst. own
- 86.16%
- Dividend
- 6.60
- Ex-div date
- Sep 17, 2023
- 50-d avg
- 18.72
- 200-d avg
- 22.71
- 1y target
- 16.50
News
5 days ago seekingalpha.com
Medifast Is Running The Same Playbook, And I Have The Same Concerns
Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to…
5 days ago zacks.com
Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.
6 days ago seekingalpha.com
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
6 days ago marketbeat.com
What Medifast (MED) Said on Its Q3 Earnings Call
Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management…
6 days ago zacks.com
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.
1 week ago benzinga.com
Medifast Q3 2026 Earnings Call Transcript
Medifast (NYSE:MED) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
1 week ago benzinga.com
Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est
Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..
-
1 week ago benzinga.com
Medifast Sees FY2026 Adj EPS $(0.70)-$(0.45) vs $(0.94) Est; Raises FY2026 Sales Guidance from $270.000M-$300.000M to $280.000M-$300.000M vs $287.700M Est
Medifast (NYSE:MED) is looking for FY2026 Adj EPS of $(0.70)-$(0.45) vs $(0.94) analyst estimate. Raises FY2026 sales outlook from $270.000 million-$300.000 million to $280.000 million-$300.000…
-
1 week ago benzinga.com
Medifast Q3 Adj. EPS $(0.19) Beats $(0.35) Estimate, Sales $72.048M Beat $71.300M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 9.52 percent increase over losses of $(0.21) per…
-
1 week ago benzinga.com
Medifast Sees Q4 GAAP EPS $0.00-$0.25 vs $(0.12) Est; Sees Sales $55.000M-$75.000M vs $64.100M Est
Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.00-$0.25 vs $(0.12) analyst estimate. sees sales of $55.000 million-$75.000 million vs $64.100 million analyst estimate.
1 week ago businesswire.com
Medifast Announces Third Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for…
3 months ago benzinga.com
11 Consumer Staples Stocks Moving In Monday's After-Market Session
Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market session. The market value of their outstanding shares is at $108.0 million. The company's, Q2 earnings came…
-
3 months ago benzinga.com
Medifast Sees Q3 GAAP EPS $(0.65)-$(0.15) vs $(0.62) Est; Sees Sales $60.000M-$80.000M vs $67.700M Est
Medifast (NYSE:MED) is looking for Q3 GAAP EPS of $(0.65)-$(0.15) vs $(0.62) analyst estimate. sees sales of $60.000 million-$80.000 million vs $67.700 million analyst estimate.
-
3 months ago benzinga.com
Medifast Q2 Adj. EPS $(0.28) Beats $(0.65) Estimate, Sales $76.384M Beat $72.700M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.65) by 56.92 percent. This is a 227.27 percent decrease over earnings of $0.22 per…
-
3 months ago benzinga.com
Medifast Launches Trilivy, Comprehensive Metabolic Health System; Co. Also Unveils Newly Formulated Meal Replacements, Including Trilivy Reset Fueling Line Enhanced With MetaVantage Technology
The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connectionMedifast, Inc.…
-
6 months ago benzinga.com
Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est
Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.98) analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$300.000 million to…
-
6 months ago benzinga.com
Medifast Sees Q2 GAAP EPS $(1.00)-$(0.50) vs $(0.43) Est; Sees Sales $60.000M-$80.000M vs $74.700M Est
Medifast (NYSE:MED) is looking for Q2 GAAP EPS of $(1.00)-$(0.50) vs $(0.43) analyst estimate. sees sales of $60.000 million-$80.000 million vs $74.700 million analyst estimate.
-
6 months ago benzinga.com
Medifast Q1 EPS $(0.19) Beats $(0.52) Estimate, Sales $76.044M Beat $69.200M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.52) by 63.46 percent. This is a 171.43 percent decrease over losses of $(0.07) per…
6 months ago benzinga.com
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
Medifast Agrees To Nominate Steamboat Capital Partners' Parsa Kiai, Jeff Rose As Independent Director Candidates
Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to…
-
8 months ago benzinga.com
Medifast Announces Availability Of OPTAVIA's Comprehensive Metabolic Health System For Reimbursement On Select Insurance Plans Using Health Savings Accounts, Flexible Spending Accounts
Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible…
-
8 months ago benzinga.com
Stephens & Co. Maintains Equal-Weight on Medifast, Lowers Price Target to $12
Stephens & Co. analyst Jim Salera maintains Medifast (NYSE:MED) with a Equal-Weight and lowers the price target from $15 to $12.
8 months ago benzinga.com
Medifast Q4 2025 Earnings Call Transcript
Medifast Q4 2025 Earnings Call Transcript
-
8 months ago benzinga.com
Earnings Scheduled For February 17, 2026
Earnings Scheduled For February 17, 2026
8 months ago benzinga.com
What to Expect from Medifast's Earnings
What to Expect from Medifast's Earnings
-
10 months ago benzinga.com
Medifast Appoints Nicholas Johnson President, Effective Immediately; CEO Dan Chard To Step Down In June
Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health.Medifast…
12 months ago benzinga.com
Earnings Scheduled For November 3, 2025
Earnings Scheduled For November 3, 2025
-
1 year ago benzinga.com
UPDATE: Medifast Q2 EPS $0.22 Beats $(0.22) Estimate, Sales $105.600M Beat $96.100M Estimate
Medifast (NYSE:MED) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.22) by 200 percent. This is a 76.09 percent decrease over earnings of $0.92 per…
-
1 year ago benzinga.com
Medifast Q3 expected to be more than $(0.60) vs $(0.30) Est; Sees Q3 Sales $70.000M-$90.000M vs $93.800M Est
Medifast (NYSE:MED) Q3 expected to be more than $(0.60) vs $(0.30) Est. sees Q3 sales of $70.000 million-$90.000 million vs $93.800 million analyst estimate.
-
1 year ago benzinga.com
Is Medifast Gaining or Losing Market Support?
Is Medifast Gaining or Losing Market Support?
-
1 year ago benzinga.com
Medifast Q2 expected to be more than $(0.55) vs $(0.08) Est; Sees Q2 Sales $85.000M-$105.000M vs $111.20M Est
Medifast (NYSE:MED) Q2 expected to be more than $(0.55) vs $(0.08) Est. sees Q2 sales of $85.000 million-$105.000 million vs $111.20 million analyst estimate.
-
1 year ago benzinga.com
Medifast Q1 EPS $(0.07) Beats $(0.27) Estimate, Sales $115.73M Beat $110.10M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.27) by 74.07 percent. This is a 110.61 percent decrease over earnings of $0.66 per…
-
1 year ago benzinga.com
Uncovering Potential: Medifast's Earnings Preview
Uncovering Potential: Medifast's Earnings Preview
-
1 year ago benzinga.com
How Is The Market Feeling About Medifast?
How Is The Market Feeling About Medifast?
-
1 year ago benzinga.com
DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $16.5
DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Neutral and lowers the price target from $17 to $16.5.
1 year ago benzinga.com
Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday?
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors.
-
1 year ago benzinga.com
Medifast Q1 expected to be $0 to $(0.50) vs $(0.19) Est; Sees Q1 Sales $100.000M-$120.000M vs $130.75M Est
Medifast (NYSE:MED) Q1 expected to be more than $(0.50) vs $(0.19) Est. sees Q1 sales of $100.000 million-$120.000 million vs $130.75 million analyst estimate.
-
1 year ago benzinga.com
Medifast Q4 Adj $0.10 Beats $(0.16) Estimate, Sales $119.00M Beat $114.25M Estimate
Medifast (NYSE:MED) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.16) by 162.5 percent. This is a 90.83 percent decrease over earnings of $1.09 per…
-
1 year ago benzinga.com
Earnings Scheduled For February 18, 2025
Earnings Scheduled For February 18, 2025
-
1 year ago benzinga.com
Medifast Announces OPTAVIA ASCEND High-Protein, Fiber-Rich Mini Meals And Daily Nutrient Packs Aimed At Maintaining Lean Muscle Mass For GLP-1 Medication Users And Weight Management Support
Two new programs incorporate OPTAVIA ASCEND products for easy nutrition, with or without medications, and provide strategies & support to help with weight maintenanceHigh-protein products help…
-
1 year ago benzinga.com
Looking Into Medifast's Recent Short Interest
Looking Into Medifast's Recent Short Interest
-
1 year ago benzinga.com
DA Davidson Upgrades Medifast to Neutral, Raises Price Target to $17
DA Davidson analyst Linda Bolton Weiser upgrades Medifast (NYSE:MED) from Underperform to Neutral and raises the price target from $16.5 to $17.
-
1 year ago benzinga.com
Medifast Sees Q4 GAAP EPS $0.10-0.65 vs $(0.18) Est; Sees Sales $100.000M-120.000M vs $129.95M Est
Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.10-0.65 vs $(0.18) analyst estimate. sees sales of $100.000 million-120.000 million vs $129.95 million estimate.
-
1 year ago benzinga.com
Medifast Q3 2024 Adj. EPS $0.35 Beats $(0.28) Estimate, Sales $140.163M Beat $134.150M Estimate
Medifast (NYSE:MED) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $(0.28) by 225 percent. The company reported quarterly sales of $140.163 million which…
-
2 years ago benzinga.com
Medifast Q2 2024 Adj. EPS $0.92 Beats $0.39 Estimate, Sales $168.558M Miss $174.050M Estimate
Medifast (NYSE:MED) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.39 by 135.9 percent. The company reported quarterly sales of $168.558 million which…
-
2 years ago benzinga.com
DA Davidson Maintains Underperform on Medifast, Maintains $17.5 Price Target
DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Underperform and maintains $17.5 price target.